제목[2020.02.28] Gwang Hyeon Eom (엄광현), Chonnam National University Medical School2020-02-26 13:34:55
작성자 Level 10

NIH-Monthly Seminar (February 28th- 엄광현 교수님)

 

Dear NIH-Korean Scientists,

 

We will have the 1st NIH-KSA seminar on February 28th (Next Fri.) 1p.m. Lunch will be provided by Psomagen, Inc.

We hope to see you there!

 

올해 첫번째 NIH-KSA세미나가 다음주 금요일 228 1시에 있을 예정입니다.

Psomagen, Inc 점심 제공합니다. 여러분의 많은 참여 부탁드립니다.

 

Time (강연시간): February 28th (Fri), 13:00-14:00 PM (45 min seminar, 15 min Q&A)

장소: NIH Bethesda Campus, Building 10, FAES Room 7 - B1C206

 

SPEAKER INFORMATION

Name(성함):  Gwang Hyeon Eom (엄광현)

Position and Department (직장과 직함): Department of Pharmacology

Chonnam National University Medical School, Gwangju, Korea

 

Seminar Title (강연제목):

S-Nitrosylation of histone deacetylase 2 by neuronal nitric oxide synthase as a mechanism for heart failure with preserved ejection fraction

 

Abstract (초록)

Background - Although the clinical importance of heart failure with preserved ejection fraction (HFpEF), which makes up half of heart failure, has been extensively explored, most therapeutic regimens, including nitric oxide (NO) donors, lack therapeutic benefit. Here we report that neuronal nitric oxide synthase (nNOS, also known as NOS1) induces HFpEF by S-nitrosylation of histone deacetylase 2 (HDAC2).

Methods – Two animal models of HFpEF—SAUNA (SAlty drinking water/Unilateral Nephrectomy/Aldosterone) and mild transverse aortic constriction (TAC) mice—were used for the study.

Results - Among the post-translational modifications tested, S-nitrosylation was dramatically increased. Both models showed increased nNOS expression and NO production, which resulted in the S-nitrosylation of HDAC2 C262/274. HFpEF was alleviated in S-nitrosylation-resistant HDAC2 knock-in mice. Pharmacologic intervention by either nNOS inhibition or HDAC2 denitrosylation attenuated HFpEF.

Conclusions - Our observations are the first to demonstrate a completely new mechanistic aspect in HFpEF, which may provide a novel therapeutic approach to HFpEF. Our results also provide evidence to explain the ineffectiveness of conventional NO-enhancement trials for improving HFpEF.

 

댓글
자동등록방지
(자동등록방지 숫자를 입력해 주세요)